WO2004083387A3 - Anticorps anti-gangliosides et procedes d'utilisation correspondants - Google Patents

Anticorps anti-gangliosides et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2004083387A3
WO2004083387A3 PCT/US2004/007524 US2004007524W WO2004083387A3 WO 2004083387 A3 WO2004083387 A3 WO 2004083387A3 US 2004007524 W US2004007524 W US 2004007524W WO 2004083387 A3 WO2004083387 A3 WO 2004083387A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
ganglioside
tumor cell
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/007524
Other languages
English (en)
Other versions
WO2004083387A2 (fr
Inventor
Gary R Fanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO2004083387A2 publication Critical patent/WO2004083387A2/fr
Publication of WO2004083387A3 publication Critical patent/WO2004083387A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à des procédés pour inhiber l'induction de l'apoptose des lymphocytes T par une cellule tumorale. Ces procédé peuvent servir notamment à bloquer l'apoptose des lymphocytes T induite par une cellule tumorale produisant la surexpression d'un ganglioside, tel qu'un monosialo-GM2. Ces procédés peuvent être utiles dans le traitement du cancer. Ces procédés consistent à mettre le ganglioside se trouvant sur la cellule tumorale en contact avec un anticorps ou un fragment de fixation d'antigène de cet anticorps, qui se lie spécifiquement au ganglioside. Ces anticorps peuvent être par exemple des anticorps de hamster, des anticorps de hamster/humains chimériques ou des anticorps humanisés.
PCT/US2004/007524 2003-03-13 2004-03-11 Anticorps anti-gangliosides et procedes d'utilisation correspondants Ceased WO2004083387A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45427003P 2003-03-13 2003-03-13
US60/454,270 2003-03-13

Publications (2)

Publication Number Publication Date
WO2004083387A2 WO2004083387A2 (fr) 2004-09-30
WO2004083387A3 true WO2004083387A3 (fr) 2004-11-25

Family

ID=33029868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007524 Ceased WO2004083387A2 (fr) 2003-03-13 2004-03-11 Anticorps anti-gangliosides et procedes d'utilisation correspondants

Country Status (1)

Country Link
WO (1) WO2004083387A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004689A2 (pt) 2009-09-01 2019-09-24 Lz Therapeutics Inc métodos para extração e purificação de gangliosídeos.
US9556467B2 (en) * 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003049704A2 (fr) * 2001-12-11 2003-06-19 University Of Massachusetts Anticorps utiles dans le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003049704A2 (fr) * 2001-12-11 2003-06-19 University Of Massachusetts Anticorps utiles dans le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOON D.S.B. ET AL.: "Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lypmhokine-activated killer cells", INT. J. CANCER., vol. 43, 1989, pages 857 - 862 *
ZHOU J. ET AL.: "Gangliosides enhance apoptosis of thymocytes", CELLULAR IMMUNOLOGY, vol. 183, 1998, pages 90 - 98 *

Also Published As

Publication number Publication date
WO2004083387A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2006066078A3 (fr) Anticorps specifiques de fc$g(g)riib et leurs procedes d'utilisation
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
WO2005012493A3 (fr) Anticorps anti-cd19
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2008140493A3 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
WO2009137832A3 (fr) Auto-anticorps dans la détection et le traitement du cancer
WO2004010947A3 (fr) Anticorps humanises contre le 4-1bb humain
WO2006084264A3 (fr) Variants d'anticorps et utilisations
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2006099141A3 (fr) Anticorps diriges contre la mesotheline
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO2007133822A8 (fr) Anticorps anti-gitr destinés au traitement du cancer
MX2007006921A (es) Composiciones que comprenden anticuerpos del receptor anti-factor de crecimiento tipo insulina 1 y metodos para obtener los anticuerpos.
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
WO2004008099A3 (fr) Procedes d'identification de tumeurs sensibles a un traitement par anticorps anti-erbb2
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
WO2012106556A3 (fr) Méthodes et compositions associées à l'inhibition d'igf-1r
WO2007087289A3 (fr) ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS
TW200510459A (en) RG1 antibodies and uses thereof
WO2006084075A3 (fr) Modulateurs adam-9
WO2010073012A3 (fr) Anticorps
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
WO2006130773A3 (fr) Methodes de traitement des tumeurs du cerveau a l'aide d'anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69 1 EPC

122 Ep: pct application non-entry in european phase